Navigation Links
BioMS Medical to present at BioCentury Conference
Date:3/24/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, March 24 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the BioCentury "Future Leaders in the Biotech Industry" Conference in New York.

WHEN: Thursday March 27th at 2:00pm (Eastern Time)

WHERE: The Millennium Broadway Hotel & Conference Center, New York

About BioCentury "Future Leaders in the Biotech Industry" Conference

-------------------------------------------------------------------- This conference offers senior investment professionals an opportunity to review investment opportunities: companies making the transition from the private to public equity markets, as well as public plays positioned to move between tiers based on value or milestones. For more information visit: http://www.biocentury.com/BCApp/BioCenturyCommon/BCConferences.aspx?ss=1

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking st
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical Announces 2007 Year End Results
2. BioMS Medical to present at BIO CEO & Investor Conference
3. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical announces third quarter 2007 results
7. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. BioMS Medical to present at BioContact 2007
10. BioMS Medical announces its intention to renew a normal course issuer bid
11. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The New York investment bank K...X:NEU) has agreed an AU$6.7 mil convertible note p...r. The private placement was arranged by KTA Capit...or. , New York (PRWEB) No...ment bank KTA Capital, LLC ("KTA Capital"...
(Date:11/24/2009)..., REYKJAVIK,Iceland,November24/PRNewswire-FirstCal...cedthatithasreceivednoticefrom,theNasdaqStockMarke...dedasofNovember30,2009andaForm25-NSEwillbefiledwit...vedeCODE,scommonstock,fromlistingonNasdaq,unlessth...ionsPanel.Thecompanyhasfiledsuchanappeal,which,wil...
(Date:11/24/2009)..., REYKJAVIK,Iceland,November24/PRNewswire-FirstCal...cedtheapprovalofallofits,"firstday"motionsbytheU.S...ruptcyCourt").deCODElastweekfiledavoluntarypetitio...cyCodewiththe,BankruptcyCourt. , Theordersiss...ooperateitsbusinessduringtheChapter11proceedings.I...
(Date:11/24/2009)..., SHANGHAI,Nov.24/PRNewswire-Asia/--ShanghaiBiolax...ion(SFDA)hasapprovedthe,investigationalnewdrugappl...novativeinsulinformulationtotreatdiabetes.ThisIND,...calstudy. , Diabetesisadisordercharacteristic...onsofdiabetesoftenresultinseveremicro-and,macro-va...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2
...#946; -lactamases are either plasmid or chromosoma...6; -lactam antibiotics. The majority of β -la...active site enzymes. One successful approach to co...is the use of β -lactamase inhibitors, such a...actam antibiotic 4 . , There is also a small gro...
..., , Molecular Devices Corporation,...says for proteolytic activity typically use synthe.... Enzyme selectivity is obtained by choosing a pep... site of a particular enzyme. The chromophore or f...site and enzymatic activity is detected by the inc...
..., Martin Boissonneault, Esther Tremblay, Benoit Ho... Recent advances in combinatorial chemistry a...increase in both the number of compounds and poten...pment of automated liquid handling and microplate ...creased throughput. Concomitantly, the introductio...
Other Biology Technology:A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 2A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 3A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 4A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 5A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 6Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 2Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 3Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 4Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 5Fluorometric Protease Assays in the SpectraMax Gemini Microplate Spectrofluorometer: Example Using Caspase3 (MaxLine Application Note #35) 6Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 2Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 3Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 4Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets. 5
(Date:11/23/2009)...D.C. The community-associated strain of the deadl...tant to most common antibioticsposes a far greater... its way into hospitals, according to a study in t... . , The new threat is easily picked up in fitn...has increased the overall burden of MRSA within ho...
(Date:11/23/2009)...CT Current research suggests that a common oral b...elated report by Nichols et al, "Unique Lipids fro...f TLR2 Ligands Capable of Enhancing Autoimmunity,"...an Journal of Pathology . , Multiple sclerosis (... brain and spinal cord, affects nearly 1 in 700 pe...
(Date:11/23/2009)...AM, Ala. A new study by University of Alabama at ...index (BMI) and co-existing medical conditions (co...observed among African-Americans compared to Cauca...lished online Nov. 23 in Cancer , a journal of th...es that although BMI and co-morbidity are independ...
Breaking Biology News(10 mins):New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Battered Womens Ills Go Beyond Bruises 59314 1Battered Womens Ills Go Beyond Bruises 59314 2Gene mingling increases sudden death risk 10325 1Gene mingling increases sudden death risk 10325 2Gene mingling increases sudden death risk 10325 3With Hormone Therapy Tender Breasts May Signal Cancer Risk 59307 1With Hormone Therapy Tender Breasts May Signal Cancer Risk 59307 2With Hormone Therapy Tender Breasts May Signal Cancer Risk 59307 3
...e and Gene Therapy Institute (VGTI) at Oregon Heal...certain white blood cells literally eat virus-infe...ic level. The research not only helps provide a cl...t also offers hope of a new method for gauging vac...he current edition of the journal Nature Medicine....
...eurons may have been a key factor in why the human...latives. In a study comparing the genomes of human...chers at the U.S. Department of Energy,s Lawrence ...int Genome Institute (JGI) found a strikingly high...at appear to regulate genes involved in nerve cell...
...of the time, they are nothing but a cosmetic nuisa...s called melanocytes start dividing abnormally to ... About one in 65 Americans born this year will be...r lifetime. , Scientists know that 30 percent of ...ercent of moles contain cancer-causing mutations. ...
Other Biology News:OHSU researchers demonstrate how white blood cells cannibalize virus-infected cells 2Neuron cell stickiness may hold key to evolution of the human brain 2Neuron cell stickiness may hold key to evolution of the human brain 3Neuron cell stickiness may hold key to evolution of the human brain 4Why don't all moles progress to melanoma? 2Why don't all moles progress to melanoma? 3
... P is the latest entry in the Biomek line. With a...tional accuracy and increased robustness, it can m...n be configured with either one or two pipetting p... sets the standard for flexible laboratory soluti...
Costar 96-Well Flat-Bottom EIA Plates, polystyrene, 100 from Bio-Rad
...DR1 Shift Assay provides a convenient method to pr... transport of MDR1 substrates. Thus, the kit may b...cules act as transport substrates for MDR1. Becaus...sence of MDR1 substrates, the MDR1 Shift Assay can...
Polaroid Wide and Long Electrophoresis Hood from Bio-Rad
Biology Products: